Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Lu CW, Pang JS, Ko YS, Chang CJ, Wang CW, Chen WT, Chen CB, Hui RC, Hung SI, Lu LY, Lu KL, Wang CL, Wu CE, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Chen MJ, Chung WH. Lu CW, et al. Among authors: ko ys, ko hw. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):328-339. doi: 10.1111/jdv.18703. Epub 2022 Nov 16. J Eur Acad Dermatol Venereol. 2023. PMID: 36366861
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP. Liu CY, et al. Among authors: ko hw. J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45. doi: 10.1007/s00432-009-0634-0. J Cancer Res Clin Oncol. 2010. PMID: 19572148
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
Liu CY, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY, Yang CT. Liu CY, et al. Among authors: ko hw. Oncotarget. 2017 Jun 27;8(57):97602-97612. doi: 10.18632/oncotarget.18746. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228636 Free PMC article.
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS, Wang CC, Huang YC, Pavlidis S, Liu CY, Ko HW, Chung FT, Lin TY, Wang CL, Guo YK, Yang CT. Kuo CS, et al. Among authors: ko hw. Thorac Cancer. 2019 May;10(5):1158-1166. doi: 10.1111/1759-7714.13057. Epub 2019 Apr 5. Thorac Cancer. 2019. PMID: 30950239 Free PMC article.
133 results